Overview

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Status:
Not yet recruiting

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

This is a phase Ⅲ, multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of narlumosbart (JMT103) in patients with unresectable or surgically difficult giant cell tumor of bone (GCTB). This clinical trial study hypothesizes narlumosbart administration groups are not inferior to active control administration groups.

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai JMT-Bio Inc.

Treatments:

Denosumab